Detection of SARS-CoV-2 virus via dynamic light scattering using antibody-gold nanoparticle bioconjugates against viral spike protein

Patricia Bento da Silva,Jaqueline Rodrigues da Silva,Mosar Corrêa Rodrigues,Julia Augusto Vieira,Ikaro Alves de Andrade,Tatsuya Nagata,Alexandre Silva Santos,Sebastião William da Silva,Marcia Cristina Oliveira da Rocha,Sônia Nair Báo,Pedro M Moraes-Vieira,José Proença-Modena,Monara K C Angelim,Gabriela Fabiano de Souza,Stefanie Primon Muraro,André Luis Branco de Barros,Glêndara Aparecida de Souza Martins,Fátima Ribeiro-Dias,Giovanna Machado,Melissa Regina Fessel,Ana Marisa Chudzinski-Tavassi,Célia Machado Ronconi,Debora Gonçalves,Rui Curi,Osvaldo N Oliveira,Ricardo Bentes Azevedo
DOI: https://doi.org/10.1016/j.talanta.2022.123355
IF: 6.1
2022-06-01
Talanta
Abstract:Mass testing for the diagnosis of COVID-19 has been hampered in many countries owing to the high cost of genetic material detection. This study reports on a low-cost immunoassay for detecting SARS-CoV-2 within 30 min using dynamic light scattering (DLS). The immunosensor comprises 50-nm gold nanoparticles (AuNPs) functionalized with antibodies against SARS-CoV-2 spike glycoprotein, whose bioconjugation was confirmed using transmission electron microscopy (TEM), UV-Vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), and surface-enhanced Raman scattering spectroscopy (SERS). The specific binding of the bioconjugates to the spike protein led to an increase in bioconjugate size, with a limit of detection (LOD) 5.29 × 103 TCID50/mL (Tissue Culture Infectious Dose). The immunosensor was also proven to be selective upon interaction with influenza viruses once no increase in size was observed after DLS measurement. The strategy proposed here aimed to use antibodies conjugated to AuNPs as a generic platform that can be extended to other detection principles, enabling technologies for low-cost mass testing for COVID-19.
What problem does this paper attempt to address?